Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), today announced its largest portfolio expansion in Australia ...
Tilray Brands TLRY announced an expansion of its medical cannabis portfolio in Australia, despite a challenging market environment. The expansion includes new products under its Redecan and Good ...
The largest systematic review, published in The Lancet Psychiatry, finds medical cannabis does not benefit anxiety, depression, or PTSD and highlights risks, questioning current prescriptions A major ...
Key Takeaways A review of 54 trials found cannabis was not beneficial for most mental health conditionsNo strong evidence was found for anxiety, PTSD or psychotic disordersSome small benefits were ...
A large umbrella review has found no strong evidence to date that medicinal cannabis can effectively treat several mental ...
Many people say they use cannabis for their mental health, but researchers find there is little to no evidence that cannabis can be beneficial for any psychiatric condition.
There’s “no evidence” that medical marijuana is effective in treating anxiety, depression or post-traumatic stress, according ...
A new study out of Australia says there's no evidence that marijuana relieves anxiety, depression or PTSD. The paper was published in The Lancet Psychiatry and researchers analyzed dozens of trials ...
Many people say they use cannabis for their mental health, but researchers find there is little to no evidence that cannabis can be beneficial for any psychiatric condition.
A new analysis represents the largest effort yet to systematically parse all the data from high-quality clinical trials on cannabis and mental health. The evidence is lacking.
A landmark Lancet Psychiatry paper published today – the largest-ever review of the safety and efficacy of cannabinoids ...
Increasing numbers of Australians are using medicinal cannabis for anxiety, depression, insomnia, substance disorders and ...